美国新生血管性年龄相关性黄斑变性患者抗血管内皮生长因子治疗的停药与治疗间隔
该回顾性临床队列研究基于美国IBM MarketScan商业与Medicare补充数据库2011年7月1日至2017年6月30日首次接受抗VEGF治疗的8167例新生血管性年龄相关性黄斑变性患者,分析24个月时治疗间隔与后续停药的关系。结果显示24至60个月总体停药率为30.4%,较短治疗间隔者更可能持续治疗(4周组76.8% vs >12周组60.6%),相比8周组,4周组停药可能性降低28%(HR 0.72),>12周组停药可能性升高55%(HR 1.55)。
要点
- 24至60个月期间抗VEGF总体停药率为30.4%。
- 60个月时持续治疗比例从4周组的76.8%降至>12周组的60.6%。
- 相比8周组,4周组停药HR为0.72,>12周组停药HR为1.55。
核心结论
- 24个月时抗VEGF治疗间隔较长的nAMD患者随后数年停药率持续高于间隔较短者。
- 作者指出这凸显了支持和教育长治疗间隔患者继续治疗的必要性。
研究设计与样本
- 回顾性临床队列研究,基于美国IBM MarketScan商业与Medicare补充保险索赔数据。
- 纳入2011年7月1日至2017年6月30日首次接受抗VEGF治疗的成人nAMD患者。
- 分析纳入8167例连续单眼抗VEGF治疗至少24个月的患者。
- 采用Kaplan-Meier曲线分析停药比例,Cox比例风险模型检验24个月时治疗间隔与停药的关联。
主要发现
- 从治疗开始24个月至60个月,总体停药率为30.4%。
- 60个月时,较短治疗间隔组持续治疗比例高于较长间隔组,从4周组的76.8%到>12周组的60.6%。
- 相比8周组,4周组停药可能性降低28%(HR [SE] 0.72 [0.12],P < .01)。
- 相比8周组,>12周组停药可能性升高55%(HR [SE] 1.55 [0.07],P < .01)。
- 各治疗间隔组的基线人口学和临床特征均衡。
临床怎么用
- 作者指出需支持和教育长治疗间隔患者继续治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the association between treatment interval and likelihood of anti-vascular endothelial growth factor (anti-VEGF) discontinuation among patients with neovascular age-related macular degeneration (nAMD) in a real-world setting in the United States. DESIGN: Retrospective clinical cohort study. METHODS: Health insurance claims data from the IBM MarketScan Commercial and Medicare Supplemental databases were retrospectively reviewed to identify adults with nAMD who received anti-VEGF for the first time between July 1, 2011, and June 30, 2017. The proportion of discontinued patients was analyzed using Kaplan-Meier curves. Cox proportional hazards models were used to examine the association between treatment intervals at 24 months and anti-VEGF discontinuation. RESULTS: The analysis included 8167 patients on continuous, unilateral anti-VEGF treatment for at least 24 months. Baseline demographics and clinical characteristics were well balanced between treatment interval groups. The overall rate of discontinuation from 24 months until 60 months after treatment initiation was 30.4%. At 60 months, patients on shorter treatment intervals were more likely to remain on treatment than those on longer intervals, ranging from 76.8% (4-week interval group) to 60.6% (>12-week interval group) and corresponding to a 28% lower likelihood (HR [SE] 0.72 [0.12], P < .01) and 55% higher likelihood of discontinuing treatment (HR [SE] 1.55 [0.07], P < .01), respectively, compared with the 8-week group. CONCLUSIONS: nAMD patients on longer anti-VEGF treatment intervals at 24 months had consistently higher discontinuation rates than patients on shorter intervals in the following years. This highlights the need to support and educate patients on long treatment intervals to continue with their treatment.
引用
- Bakri SJ, Karcher H, Andersen S, et al. Anti-Vascular Endothelial Growth Factor Treatment Discontinuation and Interval in Neovascular Age-Related Macular Degeneration in the United States. Am J Ophthalmol. 2022. PMID: 35738393. doi:10.1016/j.ajo.2022.06.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。